Palliative Single 8 Gy Radiotherapy for Symptomatic Aggressive Lymphomas 2666 Ａ -408 Oguchi M, Eba J, Tanaka O, Kozuka T, Murofushi K, Toshiyasu T, Tsurugai.

Slides:

Advertisements

Similar presentations

Background/Purpose ATRT is a rare and aggressive CNS tumor usually presenting in very young children (age less than 5 years). Aggressive treatments have.

Advertisements

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.

Rib fracture after 177 patients with Hiroshi Onishi, Hiroshi Onishi, Rihito Tominaga, Marino, Takafumi Komiyama, Kengo University of Yamanashi,

Palumbo A et al. Proc ASH 2012;Abstract 446.

Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Successful treatment of pediatric desmoid tumors using hydroxyurea Naomi Balamuth, M.D. Richard Womer, M.D. November 13, 2008.

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

Mak KS, 1 Miller RC, 2 Krishnan S, 3 Laperriere N, 4 Micke O, 5 Rutten I, 6 Kadish SP, 7 Ozsahin M, 8 and Mirimanoff RO 8 1 Harvard Medical School, Boston,

Progression-Free Interval After RFA of Lung Tumors Size Matters

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

ICNCT-16, , Helsinki, Finland

Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.

Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.

Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.

PHASE I TRIAL OF CONCURRENT CHEMORADIOTHERAPY USING DOXIFLURIDINE AND PACLITAXEL IN ADVANCED BREAST CANCER H.Hirowatari 1, K. Karasawa 1,2,

Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:

Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.

We retrospectively analyzed 58 patients with ONSM treated between on a dedicated 6 MV stereotactic LINAC. All cases were discussed in a multidisciplinary.

Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

Jens Jakob 1 ; Anna Simeonova 2 ; Bernd Kasper 3 ; Ulrich Ronellenfitsch 1 ; Frederik Wenz 2 ; Peter Hohenberger 1 1 Department of Surgery, 2 Department.

Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

1 Presented by Martin Cohen, M.D. at the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

1 NDA Nelarabine. 2 Proposed Indication Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (ALL) and.

핵의학과 PK 18 조 68 번 주리히 Case presentation 2 Disease review 3 Journal review.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry Bradford Hoppe MD, MPH William.

BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.

Locally Recurrent Head and Neck Cancer (Salvage IMRT - Dose, fractionation, volumes) Eddy S. Yang, MD, PhD Professor and Vice Chair of Translational Sciences.

Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.

Non-Hodgkin’s Lymphoma

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy plus Rituximab vs CHOP Chemotherapy plus Iodine-131-Tositumomab for the Treatment.

NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma

Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma

Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.

Reeder CB et al. ASCO 2009; Abstract (Poster)

Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Director Department of Pediatric Hematology & Oncology Delhi, INDIA.

IMRT delivery of preoperative, high dose radiotherapy to a large volume, with Simultaneous Integrated Boost (SIB) in retroperitoneal sarcomas: The Ottawa.

*Can the volume predict the acute reactions ?

Response to chemotherapy

Intervista a Lucio Crinò

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

CTCL: INNOVATIVE TREATMENTS GEMCITABINE

Gordon LI et al. Proc ASH 2010;Abstract 415.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Bradford Hoppe MD, MPH William Hartsell, MD

Results: Purpose/Objectives: Methods: Conclusions:

Presentation transcript:

Palliative Single 8 Gy Radiotherapy for Symptomatic Aggressive Lymphomas 2666 Ａ -408 Oguchi M, Eba J, Tanaka O, Kozuka T, Murofushi K, Toshiyasu T, Tsurugai Y, Onoe T, Nose T, Yamashita T. Dept. Radiation Oncology. Cancer Institute Hospital The Japanese Foundation for Cancer Research, Tokyo

Background Several studies have shown the value of 4 Gy involved field radiotherapy (IFRT) in recurrent indolent lymphomas. Aggressive lymphomas have been initially treated with higher dose of IFRT than indolent lymphomas. The palliative radiotherapy for aggressive lymphomas has rarely been documented.

AuthorTitleJournalyear Murthy VEfficacy of palliative low-dose involved field radiation therapy in advanced lymphoma: a phase II study. Clin Lymphoma & Myeloma 2008 Haas RLEffective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non- follicular lymphoma patients. Eur J Cancer2005 Haas RLHigh response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol2003 Johannsson JPhase II study of palliative low-dose local radiotherapy in disseminated indolent non- Hodgkin’s lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 2002 Sawyer EJLow dose palliative radiotherapy in low grade non- Hodgkin’s lymphoma. Radiother Oncol 1997

Purpose/Objective To determine the efficacy and safety of single 8 Gy palliative radiotherapy for patients with symptomatic refractory or advanced aggressive lymphomas.

Materials/Methods: This retrospective analysis consists of 75 sites in 28 patients with refractory aggressive lymphomas and impaired PS. The 8 Gy single fractionation involved field radiotherapy was administered in each site with appropriate techniques from 2002 to (PTV = GTV + 1 cm margin)

Patients: Their symptoms included pain, discomfort, bulky mass, jaundice and obstruction. Median age was 72 years old (range: 40-94). A median of 3 prior regimens of intensive chemotherapy were proceeded local palliative radiotherapy. The median follow up was 6 months. (range: 3-40)

Pathologyn DLBCL18 PTCL (AILT)4 (1) MCL2 ALCL3 NKTL1 PS(ECOG)n

Results: Effectiveness Median time to symptomatic progression was 4 months (range: 0-40). Symptomatic Response% CR4131/75 PR4836/75 SD/PD118/75 89%

Results: Effectiveness Median time to progression in tumor size was 4 months (range: 0-40). Response in Tumor size% CR3526/73 PR2922/73 SD/PD3627/73 64%

Results: Toxicity Temporary grade 1 acute mucositis was found in 3 sites irradiated to the head & neck mass. Retreatment was needed for 5 sites due to their persistent pain.

Case presentation Pre-XRT Gad-T1 MR Post-XRT: 7 months PET/CT

Conclusions Palliative radiotherapy of 8 Gy single fractionation is valuable asset in the management of patients with symptomatic refractory or advanced aggressive lymphomas.

Acknowledgement Cancer Institute Hospital Dept. Medical Oncology / Hematology Drs. Hatake, Terui, Yokoyama, etc Cancer Institute Dept. Pathology Dr. Takeuchi K.